Page last updated: 2024-09-05

enzastaurin and sirolimus

enzastaurin has been researched along with sirolimus in 8 studies

Compound Research Comparison

Studies
(enzastaurin)
Trials
(enzastaurin)
Recent Studies (post-2010)
(enzastaurin)
Studies
(sirolimus)
Trials
(sirolimus)
Recent Studies (post-2010) (sirolimus)
188529920,7112,36811,516

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)sirolimus (IC50)
Bile salt export pumpHomo sapiens (human)10
ATP-dependent translocase ABCB1Homo sapiens (human)1.25
Cytochrome P450 3A4Homo sapiens (human)2
Cytochrome P450 2C9 Homo sapiens (human)2
Peptidyl-prolyl cis-trans isomerase FKBP1AMus musculus (house mouse)0.001
Cytochrome P450 2C19Homo sapiens (human)4
Serine/threonine-protein kinase mTORHomo sapiens (human)0.0897
Peptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)0.0042
Regulatory-associated protein of mTORHomo sapiens (human)0.225
Target of rapamycin complex subunit LST8Homo sapiens (human)0.225
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.9
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)1.1

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Stummer, W1
Ogura, M2
Kim, KW; Lu, B; Moretti, L; Niermann, KJ; Quarles, CC; Tawtawy, MN; Tu, T; Willey, CD; Xiao, D1
Hagemeister, FB1
Ciaccio, MF; Cohen, EE; Jones, RB; Kuo, WL; Lingen, M; Liu, J; Rosner, MR; Seiwert, TY1
Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S1

Reviews

2 review(s) available for enzastaurin and sirolimus

ArticleYear
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Gene Targeting; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Prednisone; Prognosis; Purine Nucleosides; Pyrimidinones; Risk; Rituximab; Salvage Therapy; Sirolimus; Transplantation, Autologous; Vincristine

2008
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
    Current oncology reports, 2010, Volume: 12, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome

2010

Trials

1 trial(s) available for enzastaurin and sirolimus

ArticleYear
[Current development of new drugs in malignant lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat

2012

Other Studies

5 other study(ies) available for enzastaurin and sirolimus

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Perspectives in central nervous system malignancies.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases

2006
Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
    International journal of radiation oncology, biology, physics, 2010, Aug-01, Volume: 77, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Endothelium, Vascular; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2010
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Head and Neck Neoplasms; In Situ Nick-End Labeling; Indoles; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2011
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Everolimus; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Indoles; Lymphoma, Mantle-Cell; Phosphorylation; Phosphorylcholine; Protein Kinases; Quinolines; Sirolimus

2012